Novo Nordisk A/S holds the cleaner structural position, with the lead spread across growth and profitability. United Therapeutics still has the edge on stability, which keeps the comparison from looking entirely one-sided. In the market, United Therapeutics carries the stronger setup — intact trend against Novo Nordisk A/S's broken trend. That leaves a split case: the structural lead stays with Novo Nordisk A/S, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (NOVO-B.CO: STOXX 600, UTHR: Russell 1000).
The lead is spread across growth and profitability, rather than sitting in one isolated gap. Novo Nordisk A/S leads by 24 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
The clearest structural overlap shows up in margin consistency and revenue growth trajectory.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
Novo Nordisk A/S looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where NOVO-B.CO and UTHR each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
One company is still expanding while the other is contracting, which creates a very wide growth split.
On the market side, United Therapeutics carries the stronger trend while Novo Nordisk A/S's trend has broken — the market setup does not confirm the structural advantage.
The lead is built on both growth and profitability — though stability still provides a counterweight.
Break down the NOVO-B.CO vs UTHR comparison across all dimensions with the full interactive tool.
Explore how NOVO-B.CO and UTHR each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.